ANAB
AnaptysBio, Inc.
NASDAQ · USHealthcareBiotechnology
$50.29-13.29%
Price as of Jul 20, 2026
ANAB profitability
AnaptysBio, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 116.4%
- EBITDA margin
- 25.2%
- EBIT margin
- 17.6%
- Net margin
- -11.5%
- Free cash flow margin
- 1.9%
Returns
- Return on equity
- -210.1%
- Return on assets
- -8.1%
- Return on invested capital
- 14.1%
- Asset turnover
- 0.67x
Cash efficiency
- Cash from operations
- $4.5M
- Cash per share
- $9.84
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.